
Keywords: Liver Cancer; Genomics; Signaling Pathways; Molecular Therapies; AFB1; aflatoxin B1; EGF; epidermal growth factor; HBV; hepatitis B virus; HCC; hepatocellular carcinoma; HCV; hepatitis C virus; HGDN; high-grade dysplastic nodules; LGDN; low-grade dysplast